{"id":36907,"date":"2021-11-11T11:24:34","date_gmt":"2021-11-11T11:24:34","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=36907"},"modified":"2021-11-11T11:36:26","modified_gmt":"2021-11-11T11:36:26","slug":"hugo-almeida","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/irdd-speakers\/hugo-almeida\/","title":{"rendered":"Hugo Almeida"},"content":{"rendered":"
\n\n\t

Hugo Almeida<\/h2>\n

International Business Development Consultant at AdAlvo (an Alvogen subsidiary)<\/h4>\n\t

<\/p>\n

Business Development professional with a background in Pharmaceutical Sciences. Over 12 years of experience acquired in Business Development (pipeline and portfolio management), Quality and Operations, and R&D, in Pharma Industry and Academia. Most relevant experience includes building an internal pipeline of 505b2 and generic products in Ophthalmology, Dermatology and Respiratory fields. Identifying 505b2 products to be in-licensed in Respiratory, Oral and Injectable routes. Financial modeling of 505b2 and generic products in diverse therapeutic areas. Leading a cross- sectional project on handling potent compounds in a pharmaceutical facility and preparing a GMP certification of an upscale suit to produce potent compounds. In the last year, added an Executive MBA in ISEG to the Master Degree in Pharmaceutical Sciences from the University of Coimbra.<\/p>\n

<\/p>\n\t\t\t\t\t\t\t\"Hugo_Almeida_BioTech_Pharma_Summit_2021_Adalvo_gallery\"\t\t\t\t\t\t\t\n

\n\tTitle: Inhalation and Nasal routes as stairways to drug Innovation\n\t<\/h3>\n\t